Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has captured the attention of investment analysts, as Rodman & Renshaw initiated coverage with a 'Buy' rating and an $8.00 price target. The optimism centers on the company's lead drug candidate, Lucid-MS, which is being developed as a potential first-in-class non-immunomodulatory small molecule for the treatment of neurodegeneration and disability progression in progressive multiple sclerosis (MS). This area of MS has limited therapeutic options, making Lucid-MS a promising candidate for addressing a significant unmet medical need.
The $8.00 price target set by Rodman & Renshaw reflects the firm's valuation of Quantum BioPharma's development pipeline, with Lucid-MS being the cornerstone asset. Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, and the potential to reverse this process could represent a major advancement in MS treatment.
For more information on Lucid-MS, visit this link.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. The positive coverage from Rodman & Renshaw underscores the potential of Lucid-MS to become a transformative therapy for progressive MS patients, who currently have few options to halt disease progression.
The company also retains ownership in Unbuzzd Wellness Inc., which markets UNBUZZD, a product aimed at addressing alcohol misuse. Quantum retains a 19.48% ownership stake (as of June 30, 2026) in UWI, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. This diversification provides additional value to the company beyond its core MS focus.
The latest news and updates relating to QNTM are available in the company's newsroom at this link.
